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Human γδ T-cells include some of the most common “antigen-specific” cell types in 
peripheral blood and are enriched yet further at mucosal barrier sites where microbial 
infection and tumors often originate. While the γδ T-cell compartment includes multiple 
subsets with highly flexible effector functions, human mucosal tissues are dominated 
by host stress-responsive Vδ1+ T-cells and microbe-responsive Vδ2+ T-cells. Widely 
recognized for their potent cytotoxicity, emerging data suggest that γδ T-cells also 
exert strong influences on downstream adaptive immunity to pathogens and tumors, 
in particular via activation of antigen-presenting cells and/or direct stimulation of other 
mucosal leukocytes. These unique functional attributes and lack of MHC restriction have 
prompted considerable interest in therapeutic targeting of γδ T-cells. Indeed, several 
drugs already in clinical use, including vedolizumab, infliximab, and azathioprine, likely 
owe their efficacy in part to modulation of γδ T-cell function. Recent clinical trials of 
Vδ2+ T-cell-selective treatments indicate a good safety profile in human patients, and 
efficacy is set to increase as more potent/targeted drugs continue to be developed. Key 
advances will include identifying methods of directing γδ T-cell recruitment to specific 
tissues to enhance host protection against invading pathogens, or alternatively, retaining 
these cells in the circulation to limit peripheral inflammation and/or improve responses 
to blood malignancies. Human γδ T-cell control of mucosal immunity is likely exerted via 
multiple mechanisms that induce diverse responses in other types of tissue-resident 
leukocytes. Understanding the microenvironmental signals that regulate these functions 
will be critical to the development of new γδ T-cell-based therapies.
Keywords: human, mucosal, gammadelta T-cells, vdelta1, vdelta2
inTRODUCTiOn
The γδ T-cell compartment includes some of the most numerous “antigen-specific” cell types in 
peripheral blood and is enriched yet further in mucosal tissues including the lung and intestine (1, 2). 
In humans, γδ T-cells are typically divided into distinct subsets based on δ-chain usage, each being 
specialized to detect a different class of common antigen or host molecule generated by microbial 
infection, stress, and/or malignant transformation. Pathobionts frequently invade the body via 
epithelial barriers, which are also major sites of tumorigenesis, hence γδ T-cell function in mucosal 
tissues represents a critical component of host protection against a range of major diseases. While the 
ability of human γδ T-cells to lyse infected or transformed host cells has been well documented, less 
is known about their influence on downstream antimicrobial immunity and mucosal inflammation, 
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which must be carefully regulated in order to prevent autoim-
mune pathology, tissue damage, and cancer. Indeed, a recent 
analysis of tumor transcriptome data identified γδ T-cell infiltra-
tion as the best prognostic marker of survival (1), indicating that 
γδ T-cell responses can significantly influence clinical outcomes 
in human patients, but the mucosal functions of these cells and 
their impact on barrier protection remain poorly understood. 
This mini-review focuses on the potential roles of γδ T-cells in 
human mucosal tissues, with an emphasis on their ability to influ-
ence conventional leukocyte responses at these sites. We consider 
that γδ T-cell detection of stress molecules and microbial signals 
can significantly alter adaptive immunity and inflammation at 
mucosal barrier sites, consistent with the increasing recogni-
tion that tissue-resident T-cells play essential roles in human 
immunity. Where useful context has been drawn from studies 
performed in animal models, the non-human origins of these 
data have been clearly indicated.
γδ T-CeLLS MeDiATe ePiTHeLiAL 
BARRieR PROTeCTiOn
Epithelial cells are exposed to a variety of microbial and envi-
ronmental signals that induce distinct patterns of cytokine and 
chemokine secretion, as well as rapid changes in cell surface expres-
sion of host stress molecules. Acting in concert, these factors 
can stimulate a range of leukocyte responses as complex as 
those imparted by myeloid antigen-presenting cells (3). Innate-
like lymphocytes residing in the epithelial layer and underlying 
mucosa are key responders to these barrier stress signals, and γδ 
T-cells comprise a major component of this “unconventional” 
lymphocyte pool. It is well-established that epithelial signaling to 
γδ T-cells begins early, in the thymus, where these cells are imparted 
with greater gut-homing potential (integrin α4β7 expression) 
than conventional lymphocytes, and exhibit more efficient pro-
liferation upon subsequent recruitment to the murine mucosa 
(4). Less clear is how far epithelial cells continue to shape γδ 
T-cell function upon their arrival in mucosal tissues, although 
an intimate functional relationship controlled by a variety of dif-
ferent signals seems increasingly likely (5). Indeed, the γδ T-cell 
repertoire in human intestine undergoes major changes with age 
and becomes oligoclonal in adults (6), suggesting strong local 
selection by site-specific signals that include host butyrophilin-
like molecules (5, 7), dietary and microbial ligands for the aryl 
hydrocarbon receptor (8), and common pathogen products and 
stress antigens. Accordingly, studies in parabiotic mice have dem-
onstrated that the frequency of γδ T-cell mixing between animals 
is low in the gut epithelium, whereas up to 50% cell exchange 
between animals can be observed in the lamina propria (9). These 
data suggest that Vδ1+ intraepithelial lymphocytes (γδ-IEL) may 
develop in situ, whereas lamina propria γδ T-cells depend both 
on recruitment from the peripheral blood and local proliferation 
in order to maintain the local pool. In mice, it is widely accepted 
that the majority of γδ T-cells are pre-programmed with cytokine 
potential and effector functions within the thymus (10). However, 
recent data suggest that γδ T-cell function outside the thymus is 
more plastic than originally thought (11), and the murine Vγ7+ 
subset appears to require Btnl1 expression by the gut epithelium 
to develop IFNγ-expressing capacity (5). In humans, the closely 
related proteins BTNL3 and BTNL8 may similarly cooperate to 
promote colonic expansion of the analogous Vγ4+ subset (5), 
although the functional impact of this mechanism remains unclear, 
and populations expressing alternative γ-chains also reside in this 
tissue. Nonetheless, human γδ T-cell function does not appear to be 
“hard-wired” in the thymus and remains receptive to site-specific 
cues that likely induce distinct functional profiles in different tis-
sues and organs. Intriguingly, BTNL2 is primarily expressed in the 
small intestinal epithelium and appears to function as a negative 
regulator of T-cell activation (12), with mutations in this protein 
conferring increased risk of inflammatory bowel disease (IBD) 
(13). It is possible, therefore, that therapeutic strategies targeting 
BTNL molecules and/or γδ T-cell activation in the human gut may 
yield new treatment options for patients with IBD.
Consistent with a role for γδ-IEL in monitoring gut barrier 
function, recent data indicate that these cells are highly motile in 
the mouse intestine and actively scan the epithelium for signs of 
cellular stress, with pro-inflammatory cytokines and/or pathogen 
encounter significantly modulating this behavior (14, 15). Indeed, 
while γδ-IEL numbers appear largely unaffected in germ-free 
mice (16), epithelial cell contact with gut bacteria can induce 
γδ-IEL expression of antimicrobial peptides (17), confirming that 
exposure to the microbiota can significantly alter their function. 
It is likely that human gut γδ-IELs scan the epithelium for expres-
sion of MHC I-related genes MICA and MICB, which function as 
stress-inducible triggers for γδ T-cell cytotoxicity (18, 19). MICA/B 
expression has already been identified in carcinomas of the lung 
and colon, where these molecules are associated with enhanced 
tumor infiltration by cytotoxic γδ T-cells (20). Accordingly, γδ 
T-cells isolated from human lung tumors can selectively lyse 
autologous malignant cells ex vivo (21). Vδ1+ γδ T-cells also seem 
to be expanded in many transplant recipients, where they express 
gut-homing receptors and are strongly activated by intestinal 
tumor cells but not healthy epithelial cell lines (22).
MICA/B is recognized with high affinity by the natural killer 
(NK) cell receptor NKG2D (23), which is expressed by human 
γδ-IELs under the control of IL-15 (24). This cytokine appears to 
play an important role in steady-state maintenance of the murine 
γδ-IEL compartment (25), and thymic expression of IL-15 is 
required to modulate histone acetylation of the Vγ5 gene segment, 
which is preferentially used by mouse gut γδ-IELs (26). Consistent 
with these data is the observation that epithelial supply of IL-15 
cytokine plays a crucial role in γδ T-cell control of mucosal inflam-
mation in murine colitis (27). Similarly, human intestinal Vδ1+ 
T-cells are significantly expanded in both celiac disease and IBD 
(28, 29), which are characterized by high mucosal levels of the 
tissue damage-associated cytokine IL-15 (30–32). Intriguingly, 
patients with celiac disease exhibit upregulated activity of cyto-
toxic lymphocytes (24), but a subset of NKG2A+ γδ T-cells can 
reportedly decrease IFNγ expression by cocultured gut αβ T-cells 
(33). Similarly, transfer of γδ-IELs into mice that lack these cells 
can protect against chemical colitis by decreasing host lymphocyte 
expression of pro-inflammatory cytokines and modulating epi-
thelial production of IL-15 (27). These data strongly suggest that 
γδ-IELs help maintain the integrity of the epithelium by altering 
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the local activity of other gut leukocyte subsets, and that IL-15 
may alert these cells to tissue stress, including the need to remove 
infected/malignant epithelial cells from the barrier. Consequently, 
when intestinal γδ T-cells are deleted in murine models, the 
gut epithelium displays uncontrolled IFNγ expression, chronic 
inflammation, and impaired barrier regeneration (34).
Vδ1+ T-cell influences on other leukocyte populations have 
previously been reported in various settings of relevance to 
mucosal barrier protection. For example, maturation of CD1c+ 
myeloid dendritic cells (DC) can be induced by direct contact 
with CD1c-restricted Vδ1+ T-cells in vitro (35), suggesting that 
similar interactions may also occur at mucosal sites in vivo. The 
resultant mature, CD1c+ DC are endocytic, can efficiently present 
novel protein antigens, and are more potent stimulators of naïve 
T-cell proliferation than DC activated with cytokines alone. 
Intriguingly, these characteristics can also be observed in human 
lung DC isolated from patients with atopic asthma and may 
represent genuine features of mucosal inflammatory disorders 
(36). Vδ1+ T-cell-induced maturation of CD1+ myeloid DC does 
not rely on foreign antigen and is chiefly mediated by TNFα (35), 
which also triggers rapid activation of γδ T-cells (37–39), and likely 
enables timely immune responses to a barrier breach. Indeed, full 
DC maturation has long been known to require interaction with 
T-cells (40), but αβ T-cell clones with fine antigen specificity are 
rare in the periphery. Tissue-resident γδ T-cells may therefore 
accelerate DC maturation in the mucosa by relying on non-
polymorphic molecules to mediate this interaction (41). Indeed, 
increased CD1 expression by APC has already been reported 
to enhance T-cell stimulation in a murine model (42). It is also 
important to note that this model does not preclude a role for the 
microbiota, since microbial antigen can enhance APC presenta-
tion of self-antigens to CD1-restricted T-cells (43). Indeed, CD1+ 
DC can also present pollen-derived lipid antigens to Vδ1+ T-cells 
derived from the blood of allergic donors (44), suggesting that 
similar interactions can also occur in the human lung in allergic 
asthma. While it is unclear to what extent laboratory mice can 
accurately model asthma pathology (45), previous studies have 
observed a major influence of lung γδ T-cells on allergen-induced 
airway hyperreactivity and excess production of IgE (46, 47), 
which are cardinal features of the human disease. Intriguingly, 
these effects were again associated with a shift in cytokine produc-
tion by pulmonary αβ T-cells, further suggesting that γδ T-cells 
can exert complex effects via their influence on other mucosal 
leukocyte populations. Indeed, gut-tropic γδ T-cells can promote 
Th1/Th17 differentiation of CD4+ T-cells in  vivo to exacerbate 
colitis in murine models (48, 49), and a Vδ2+ subset expressing 
the PD1 isoform Δ42 promotes gut inflammation in humanized 
mice via putative effects on DC (50). Together, these data suggest 
that γδ T-cells may exert similarly potent influences on adaptive 
immunity and inflammation in human mucosal tissues.
γδ T-CeLLS STiMULATe COMPLeX 
MUCOSAL LeUKOCYTe ReSPOnSeS
Often referred to as rare cells, recent estimates suggest that the 
phosphoantigen-responsive Vδ2+ population in fact accounts 
for ~1 in 40 memory T-cells in healthy adults and may represent 
the single largest recall response in the human body (2, 51). Indeed, 
Vδ2+ T-cells are capable of expanding yet further to dominate the 
blood lymphocyte pool in a wide range of infections (52, 53), which 
has led to extensive study of these cells in the circulation as well as 
the common misconception that they are restricted to the blood. 
However, several reports have now identified that the majority of 
blood Vδ2+ T-cells express homing receptors for epithelial barrier 
sites including the skin (CLA) and intestine (integrin α4β7 and 
CCR9) (50, 54, 55). This tissue-tropic phenotype is consistent 
with the role of Vδ2+ T-cells in host protection against pathogens 
that colonize epithelial barriers and produce the metabolite (E)-
4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) (56). 
Indeed, while circulating Vδ2+ T-cells are well situated to detect 
host cell accumulation of phosphoantigen in blood malignancies 
(57), the majority of non-hematological cancers are epithelial in 
origin, such that Vδ2+ T-cell recruitment to these sites is likely to 
enhance tumor surveillance as well as antimicrobial immunity. 
Vδ2+ T-cells express high levels of α4β7 in humans (22, 55, 58), 
are rapidly recruited to mucosal tissues in higher primates in vivo 
(59, 60), and mediate effective host protection against bacteria 
in humanized mice (61). Recent work in a macaque model also 
demonstrated that injection of HMB-PP or related compounds 
stimulates Vδ2+ T-cell expansion in the blood and accumulation 
of a CD27+ IFNγ-producing subset in the lungs (59). Intriguingly, 
lung accumulation of Vδ2+ T-cells persisted for several months 
and was associated with a corresponding increase in CD4+ and 
CD8+ conventional T-cell numbers, suggesting that activation 
of mucosal Vδ2+ T-cells exerts multiple downstream effects on 
other leukocyte compartments. Indeed, Vδ2+ T-cell activation 
in  vivo has since been shown to enhance conventional Th1 
responses in the lung and promote mucosal release of growth fac-
tors that confer protection against a range of different pathogens 
(including Listeria monocytogenes, Mycobacterium tuberculosis, 
and Yersinia pestis) (60, 62, 63). Since HMB-PP injection into 
macaques promotes Vδ2+ T-cell expansion and recruitment 
to the intestinal mucosa as well as the lung (59, 60), it is likely 
that these cells exert similar effects on αβ T-cell responses and 
antimicrobial immunity in the primate gut. Consistent with this 
concept, human gut tissue contains Vδ2+ T-cells that express the 
tissue-resident memory T-cell marker CD103, exhibit distinct 
patterns of cytokine production, and modify IFNγ expression by 
autologous gut CD4+ T-cells (55, 64). In mice, T-cell entry into 
the epithelium combined with local IL-15 and TGF-β signaling 
is required for the formation of long-lived memory cells that 
express CD103 (65). Whether or not CD103+ Vδ2+ T-cells in 
human tissues represent a long-lived population with distinct 
roles in mucosal immunity is currently unclear.
We have previously demonstrated that activation of Vδ2+ 
T-cells in human intestine modulates cytokine production by 
colonic αβ T-cells in the same piece of gut tissue (55), indicating 
that these cells are present in sufficient numbers to exert potent 
effects on downstream mucosal immunity. Moreover, like Vδ1+ 
T-cells the Vδ2+ population can promote generation of mature 
DC via a TNF-dependent mechanism (66, 67), illustrating a 
marked ability of these “innate-like” cells to trigger adaptive 
immune responses. In the case of the Vδ2+ subset, this process 
FigURe 1 | Human mucosal γδ T-cells protect the epithelial barrier against microbes and tumors. Tissue-resident γδ T-cells may develop in situ under the control of 
site-specific BTNL heterodimers that maintain these cells in a primed but inactivate state (blue Vδ1+ cells). Human mucosal barrier sites are also enriched in CD1+ 
myeloid APC (orange cells) that capture microbes and may undergo local TNF-induced maturation via self-antigen presentation to CD1-restricted γδ T-cells. The 
resultant mature APC can stimulate conventional αβ T-cell responses at the site of infection without the need to migrate through the draining lymphatics. Loss of 
BTNL signaling or upregulation of MICA/B expression by the infected/transformed/stressed epithelium (red/hatched/membrane-damaged cells) also triggers γδ 
T-cell cytotoxic responses that rapidly lyse the compromised cells (gray cells; both Vδ1+ and Vδ2+ subsets). Maintenance of these “epithelial surveillance” γδ T-cell 
populations is regulated by a complex variety of signals including local provision of AhR ligands, epithelial cytokine IL-15, and growth factor TGF-β. These factors 
likely also play critical roles in promoting tissue residence of recruited γδ T-cell populations. In the case of Vδ2+ T-cells (green cells), recruitment from the blood could 
be driven by (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) translocation across the defective mucosal barrier. Accumulation of microbial HMB-PP in 
the mucosa can then trigger BTN3A-mediated activation of Vδ2+ T-cells in the presence of IL-15 to promote differentiation into potent APC (and perhaps also 
reciprocal activation of local myeloid cell populations). This process supports rapid local generation of presenting cells that can stimulate CD4+ T-cell expression of 
barrier protectant cytokines, including IFNγ and IL-22 (purple CD4+ T-cells). These mediators promote epithelial release of antimicrobial peptides (AMPs) including 
calprotectin and cooperate with TNFα to promote neutrophil activation and survival.
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also confers potent APC capacity on the γδ T-cells, likely allowing 
rapid amplification of immune responses at sites of barrier breach 
and microbial invasion. Early work in this area demonstrated 
that microbial activation induced human Vδ2+ T-cells to process 
and present antigens as efficiently as DC, as well as provide co-
stimulatory signals that stimulated naïve αβ T-cell proliferation 
and differentiation (68, 69). It is now widely recognized that 
blood Vδ2+ T-cells can display remarkably flexible APC functions, 
while the nature of the αβ T-cell responses they induce in tissues 
is likely directed by the stimuli encountered at specific anatomi-
cal sites. Indeed, “Vδ2-APC” function appears to be optimally 
induced by microenvironmental signals known to be highly 
enriched in the human gut, namely microbe-derived HMB-PP 
(70), pro-inflammatory mediator TNFα (71), and epithelial 
cytokine IL-15 (32). It is perhaps unsurprising then that human 
intestinal Vδ2-APC are efficient inducers of the barrier defense 
mediator IL-22 (72), whereas conventional myeloid APC in this 
tissue are instead specialized to induce “pro-symbiotic” IL-17 
responses (73). Intriguingly, therapeutic antibody-mediated dis-
ruption of Th17 biology led to increased mucosal inflammation 
in patients with Crohn’s disease during randomized controlled 
trials (74, 75), suggesting that Vδ2+ T-cell-directed immuno-
therapies might prove to be an effective method of enhancing 
barrier protection without impacting on mucosal levels of IL-17. 
Indeed, recruitment of circulating Vδ2+ T-cells to inflamed skin 
lesions has already been identified in patients with psoriasis (54), 
and this population can also infiltrate the peritoneal cavity in 
patients with bacterial infections (39). In both cases, local Vδ2+ 
T-cell numbers and activation state were significantly correlated 
with therapeutic/patient outcomes, suggesting that these cells 
significantly impact on the clinical course of both inflammatory 
and infectious pathologies affecting multiple human tissues.
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exposed to microbial antigens and/or host molecules commonly 
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against bacterial and fungal pathogens (77). Human γδ T-cells 
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microbial and host stress molecules and respond not only with 
rapid effector functions, but also by relaying critical information 
to other mucosal leukocyte populations. Data from our own 
laboratories indicate that human Vδ2+ T-cells can significantly 
modify intestinal immune responses via direct antigen presenta-
tion in vitro (72), and influence the clinical outcome of microbial 
infections in vivo (39), hence these cells should be a high priority 
for the development of novel immunotherapies. Indeed, a recent 
transcriptome analysis of 585 human colorectal cancer samples 
revealed that tumor infiltration by IFNγ-producing Vδ2+ T-cells 
in particular was associated with higher probability of 5-year 
disease-free survival (78). Given that γδ T-cells also exhibit potent 
activity in non-malignant settings, it seems likely that therapies 
targeting these cells could prove effective in a range of different 
pathologies. Multiple drugs already in widespread clinical use 
likely owe their therapeutic efficacy in part to modulation of γδ 
T-cell function, including the anti-α4β7 antibody vedolizumab 
(79–81), anti-TNF agents including infliximab (38, 82–85), and 
immunosuppressant drug azathioprine (86). The aminobisphos-
phonate drug zoledronate has also been shown to promote Vδ2+ 
T-cell activation in vivo by inhibiting the farnesyl pyrophosphate 
synthase enzyme to allow host cell accumulation of isopentenylpy-
rophosphate (87). Work is ongoing to identify optimal strategies 
for zoledronate adjunctive therapy, which has so far displayed 
variable patient benefit in clinical trials (88, 89). However, the 
continuing development of aminobisphosphonate pro-drugs and 
γδ-selective nanobody agonists/antagonists will soon yield more 
potent therapies for a variety of major human disorders (90–92). 
Given that γδ T-cell biology is closely associated with epithelial 
barriers, a key consideration for future treatment strategies will be 
ensuring the effective targeting of γδ T-cells to tissues of interest 
(55, 58, 93, 94). Limiting γδ T-cell egress from the blood may 
prove beneficial when treating blood malignancies and mucosal 
inflammatory disorders such as IBD (e.g., with anti-integrin 
antibodies), whereas enhancing cell migration to barrier sites will 
likely be key to enhancing protection against mucosal infection 
and epithelial tumors. The extent to which therapeutic outcomes 
are influenced by the mechanisms that promote γδ T-cell tissue 
residency will also need to be explored.
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